DBV Technologies (NASDAQ:DBVT) Shares Set to Reverse Split on Friday, November 29th

Shares of DBV Technologies S.A. (NASDAQ:DBVT) are going to reverse split on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 28th.

DBV Technologies Stock Down 3.9 %

DBVT stock opened at $0.47 on Monday. The firm has a market cap of $45.26 million, a price-to-earnings ratio of -0.52 and a beta of 0.66. DBV Technologies has a 12-month low of $0.44 and a 12-month high of $2.14. The company’s fifty day simple moving average is $0.70 and its 200 day simple moving average is $0.85.

Analysts Set New Price Targets

Several equities analysts recently issued reports on DBVT shares. HC Wainwright boosted their target price on shares of DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, October 24th. StockNews.com assumed coverage on shares of DBV Technologies in a report on Friday. They issued a “hold” rating on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price target on shares of DBV Technologies in a research note on Tuesday, September 24th.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.